A novel second line chemotherapy treatment of recurrent thymoma

Naveed Jan, Gina M. Villani, Jonathan Trambert, Carol Fehmian, Brij Sood, Peter H. Wiernik

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Thymoma is an uncommon malignancy which is initially treated with surgery. Combined modality treatment with radiation and chemotherapy is utilized in cases of unresectable or metastatic disease. In patients with relapse, a number of different chemotherapeutic regimens have been used with varying success. The case of a male with recurrent thymoma treated with carboplatin and paclitaxel is presented and the literature reviewed. The patient responded to this novel regimen with improvement in clinical symptoms and reduction in tumor mass. This novel regimen has shown activity as second line therapy and merits further investigation as a first line treatment for patients with invasive and or metastatic thymoma.

Original languageEnglish (US)
Pages (from-to)163-168
Number of pages6
JournalMedical Oncology
Issue number3-4
StatePublished - Sep 1 1997


  • Carboplatinum
  • Chemotherapy
  • Paclitaxel
  • Thymoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'A novel second line chemotherapy treatment of recurrent thymoma'. Together they form a unique fingerprint.

Cite this